MK-677 vs Mecasermin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ibutamoren, Nutrobal
MK-677 (ibutamoren) is not actually a peptide, it is a small, orally active non-peptide molecule that mimics ghrelin, your hunger and growth-hormone hormone. Taken as a daily pill, it reliably pushes up growth hormone and IGF-1 levels, which is why it is popular for muscle and recovery. It has been through real human trials but was never approved as a drug, and the trials that mattered most for older adults and Alzheimer's came up short.
Also: Increlex, rhIGF-1
Mecasermin is recombinant human IGF-1, identical to the 70-amino-acid hormone your liver makes in response to growth hormone. Sold as Increlex, it was FDA approved in 2005 for a narrow group: children with severe primary IGF-1 deficiency (mostly Laron syndrome) or a growth hormone gene deletion with antibodies against GH. In those kids it is the only thing that works, because GH cannot do its job. It is not a GH substitute, and its real risks (low blood sugar, tonsil overgrowth, cancer warnings) are why it stays a specialist drug.
Key Comparison Insights
- Mecasermin is FDA approved, while MK-677 remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Mecasermin has stronger research evidence (FDA Approved) compared to MK-677 (Human Trials).
Detailed Comparison
| Attribute | MK-677 | Mecasermin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | MK-677 is a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), the same receptor the hormone ghrelin binds. By activating that receptor in the pituitary and hypothalamus, it triggers pulses of growth hormone release, which in turn raises IGF-1 (insulin-like growth factor 1) from the liver. Because it copies ghrelin, it also tends to increase appetite, and it can nudge up cortisol levels too. The effect is sustained because it is long-acting and orally available, unlike injectable peptides that mimic ghrelin or growth-hormone-releasing hormone. | Normally, growth hormone binds receptors in the liver and other tissues and triggers IGF-1 production. IGF-1 then activates the type 1 IGF receptor on bone, cartilage and other cells, driving growth. In Laron syndrome the GH receptor is broken, so GH levels are high but IGF-1 stays low. Mecasermin skips the broken step and supplies IGF-1 directly. Because the IGF-1 receptor is a close relative of the insulin receptor, and because IGF-1 can also bind the insulin receptor at higher levels, it lowers blood sugar. That is why the label says to give it within about 20 minutes of a meal or snack. It is mostly carried by IGF binding protein 3 in blood, and its clearance depends on IGFBP-3 levels; the label reports a mean terminal half-life of about 5.8 hours in children with severe primary IGF-1 deficiency. |
| Common Dosing | 10-25 mg daily Once daily, often before bed | 0.04-0.08 mg/kg twice daily to start Twice daily |
| Administration | Oral | Subcutaneous injection, rotating sites, within about 20 minutes before or after a meal or snack |
| Typical Duration | 8-12 weeks or longer | Long-term, until growth plates close (closed epiphyses are a contraindication) |
| Best Time to Take | Before bed | Shortly before or after a meal or snack, twice daily |
Possible Side Effects May vary by individual |
|
|
| Research Summary | MK-677 has unusually good human data for a compound sold in the gray market, and the data is a mix of clear wins and clear failures. In a one-year randomized trial of 65 healthy older adults (Annals of Internal Medicine, 2008), 25 mg daily raised IGF-1 and increased fat-free mass, basically lean tissue, though much of the early body-weight gain was water and the functional strength benefits were not impressive. In Alzheimer's disease, a large 563-patient, 12-month randomized trial (Neurology, 2008) confirmed it raised IGF-1 but did nothing to slow cognitive decline. Across studies the consistent downsides are increased appetite, fluid retention, and reduced insulin sensitivity (higher blood sugar). So the muscle-and-IGF-1 effect is real and well documented, but MK-677 failed its biggest disease trials, remains unapproved, and is banned in sport by WADA. | The approval rests on five pooled studies (four open-label, one placebo-controlled) in 71 children with severe primary IGF-1 deficiency, 87% of whom had Laron syndrome. Height velocity rose from 2.8 cm per year before treatment to 8.0 cm per year in year 1, then settled around 4.5 to 5.8 cm per year in later years, still above baseline. Height scores improved but these children stayed very short (mean height SDS went from -6.7 to about -5.2 after 8 years), so it helps rather than normalizes. Hypoglycemia was reported in 42% of children at least once, and tonsillar hypertrophy in 15%. The label carries warnings for hypoglycemic seizures, anaphylaxis, intracranial hypertension, slipped capital femoral epiphysis (added July 2025), scoliosis progression, and postmarketing reports of malignant neoplasms; malignancy is a contraindication. Ownership changed recently: Eton Pharmaceuticals bought Increlex from Ipsen in December 2024 and in 2025 licensed rights outside the US to Esteve. Adult use, anti-aging use, and bodybuilding use are off-label and unsupported by trials. |
Frequently Asked Questions: MK-677 vs Mecasermin
What is the difference between MK-677 and Mecasermin?
MK-677 is a growth hormone peptide that mk-677 (ibutamoren) is not actually a peptide, it is a small, orally active non-peptide molecule that mimics ghrelin, your hunger and growth-hormone hormone. taken as a daily pill, it reliably pushes up growth hormone and igf-1 levels, which is why it is popular for muscle and recovery. it has been through real human trials but was never approved as a drug, and the trials that mattered most for older adults and alzheimer's came up short. Mecasermin is a growth hormone peptide that mecasermin is recombinant human igf-1, identical to the 70-amino-acid hormone your liver makes in response to growth hormone. sold as increlex, it was fda approved in 2005 for a narrow group: children with severe primary igf-1 deficiency (mostly laron syndrome) or a growth hormone gene deletion with antibodies against gh. in those kids it is the only thing that works, because gh cannot do its job. it is not a gh substitute, and its real risks (low blood sugar, tonsil overgrowth, cancer warnings) are why it stays a specialist drug. The main differences lie in their mechanisms of action and clinical applications.
Which is better, MK-677 or Mecasermin?
Neither is universally "better" - the choice depends on your specific goals. MK-677 is typically used for growth hormone purposes, while Mecasermin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can MK-677 and Mecasermin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using MK-677 and Mecasermin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.